Strongest evidence: Outcomes with high or moderate evidence strength include reductions in triglyceride levels (high; 5 of 6 studies, small effect), fasting blood glucose (high; 5 of 5 studies, mixed effect), and pain (moderate; 8 of 12 studies, small-to-moderate effect, with effective doses of 300–1200 mg/day curcumin). Moderate evidence also supports reductions in C-reactive protein (4 of 5 studies, moderate effect), body mass index (4 of 6 studies, small effect), total cholesterol (3 of 4 studies, small effect), and pro-inflammatory cytokines (3 of 4 studies, moderate effect).
Mixed or weaker evidence: Low-strength outcomes include hemoglobin A1c (3 of 4 studies, mixed effect, dose 1500 mg/day), HDL cholesterol (2 of 4 studies, small effect), quality of life (4 of 4 studies, mixed effect, dose ~1 g/day), inflammatory markers in exercisers (4 of 4 studies, small effect), and interleukin-6 (2 of 4 studies, moderate effect). Several of these have small evidence bases (4 studies each) and findings are considered preliminary.
Effective dose patterns: Although many studies did not report specific doses, a range of 300–1200 mg/day of curcumin or curcuminoid extracts emerges for pain reduction, while 1500 mg/day was used in a 12-month RCT for hemoglobin A1c and cytokine reduction, and 1 g/day (often with piperine) appeared in quality-of-life studies. No consistent dose was identified for lipid or glycemic outcomes.
Population insights: The majority of research involved adults with clinical conditions—type 2 diabetes, metabolic syndrome, osteoarthritis, and chronic pain—where benefits were most consistent. Effects in healthy or athletic populations were less pronounced or absent (e.g., neutral results in athletes for CRP and in small healthy cohorts).
Notable caveats: Publication bias is a recurring concern, particularly for outcomes with overwhelmingly positive results (triglycerides, fasting glucose, pain). Many studies lacked dose, form, or duration details, limiting dose-response conclusions. Several neutral studies had small sample sizes or focused on specific clinical populations (e.g., hemodialysis patients), reducing generalizability. Evidence quality for some meta-analyses was rated low or very low, and effect sizes varied substantially across conditions.